Фармацевтичний журнал (Mar 2019)
Analysis of the list of dugs for the treatment of bronchial asthma in children acording to state form
Abstract
Today, in the conditions of economic instability of the country, provision of rational pharmacotherapy is an important element of the development of the health system of Ukraine. An effective tool for this is the state form of drugs that allows to remove ineffective drugs, and the treatment of proven efficacy by evidence-based medicine. The purpose of the work was to study the lists and dynamics of the number of drugs for the treatment of bronchial asthma in children in the State form of the Ministry of Health of the first-tenth issues. Material and method of research was the content analysis of the State form for the first-tenth issues of the Ministry of Health and the Unified Clinical Protocol for Primary, Secondary (Specialized) Medical Aid «Bronchial Asthma in Children». In the results of the conducted research, the number of drugs for the treatment of asthma in children contains 13 international non-proprietary names (INNs), all of which were presented in 10 issues of the State form of drugs, except for Omalizumab, which was available in 9 out of 10 issues. In general, there is an increase number of trade names (TN) with each issue of the State form of drugs, analysis of the data carried out on chain indicators allowed to establish that the number of TN in the tenth issue compared with the first increased by 22%. A study of quantitative changes in TN shows us that for most INNs, the range of drugs increases or does not change, but the difference between the first and the tenth release of the State form of INN drugs use for Beclometasone and Methylprednisolone is – 40%. The analysis allows producing countries to establish that 87% of the analyzed group of drugs manufactured by foreign pharmaceutical companies, and only 13% – domestic. This production represented 20 foreign countries and domestic – 10 companies. The largest segment of the studied sample drugs generates India – 24.3%, Great Britain and Ukraine – by 12.6%. The conducted studies allow us to conclude that the domestic production of this group of drugs with proven efficacy and safety according to evidence-based medicine is advisable, which will reduce the total cost of treatment for asthma in children, by increasing the proportion of Ukrainian drug production.
Keywords
